Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

Aims To evaluate current evidence of glucagon-like peptide-1 receptor agonists (GLP-1RAs)
on blood pressure, heart rate, and hypertension in patients with type 2 diabetes. Methods …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-
diabetic drugs that improve glycemic control and many other atherosclerosis-related …

Background Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease
(NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes …

摘要背景: 胰高血糖素样肽‐1 (glucagon‐like peptide 1, GLP‐1) 受体激动剂对维持糖尿病患者
的体重有益. 我们通过分析以往的随机对照试验来了解该类药物在非糖尿病的肥胖/超重人群中 …

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease
(CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major …

Background Tirzepatide, a once-weekly glucose-dependent insulinotropic
polypeptide/glucagon-like peptide-1 receptor agonist, is approved in the United States …

Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent disease globally.
Current estimates are that 24% of the adult population, thus, one billion individuals …

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease
that affects more than a quarter of the global population and whose prevalence is increasing …

What is known and objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are
one of the preferred approved treatment options for people with type 2 diabetes (T2D) and …